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Abstract 
 
Lynch syndrome is an autosomal-dominant hereditary condition predisposing to the development of 
specific cancers, because of germline mutations in the DNA-mismatch repair (MMR) genes. Large genomic 
deletions represent a significant fraction of germline mutations, particularly among the MSH2 gene, in 
which they account for 20% of the mutational spectrum. In this study we analyzed 13 Italian families 
carrying MSH2 exon 8 deletions, 10 of which of ascertained Sardinian origin. The overrepresentation of 
Sardinians was unexpected, as families from Sardinia account for a small quota of MMR genes mutation 
tests performed in our laboratory. The hypothesis that such a result is owing to founder effects in Sardinia 
was tested by breakpoint junctions sequencing and haplotype analyses. Overall, five different exon eight 
deletions were identified, two of which recurrent in families, all apparently unrelated, of Sardinian origin 
(one in eight families, one in two families). The c.1277–1180_1386+2226del3516insCATTCTCTTTGAAAA 
deletion shares the same haplotype between all families and appears so far restricted to the population of 
South-West Sardinia, showing the typical features of a founder effect. The three non-Sardinian families 
showed three different breakpoint junctions and haplotypes, suggesting independent mutational events. 
This work has useful implications in genetic testing for Lynch syndrome. We developed a quick test for each 
of the identified deletions: this can be particularly useful in families of Sardinian origin, in which MSH2 exon 
8 deletions may represent 50% of the overall mutational spectrum of the four MMR genes causing Lynch 
syndrome. 
Introduction 
 
Lynch syndrome is an autosomal-dominant cancer predisposition syndrome because of germline mutations 
in the DNA-mismatch repair (MMR) genes. 
 
Individuals with Lynch syndrome carry a significant life-time risk of developing colorectal cancer, often 
diagnosed before the age of 50 years, right-sided and multiple (synchronous or metachronous). Moreover, 
the syndrome is characterized by an increased risk of cancer at other anatomical sites, including 
endometrium, ovary, upper urinary tract, stomach, small bowel, hepatobiliary tract and brain.1, 2 The main 
MMR genes are MSH2, MLH1, MSH6 and PMS2, which are responsible for recognition and repair of base–
base mismatches and small nucleotide insertions/deletions that occur during DNA replication. Molecular 
defects in these genes lead to an accumulation of mutations in somatic cells and genomic instability, thus 
promoting cancerogenesis. 
 
A significant fraction of germline mutations in Lynch syndrome is represented by large genomic 
rearrangements such as deletions, particularly in MSH2.3, 4, 5, 6, 7, 8 
 
In this paper we describe the characterization of five different MSH2 exon 8 deletions identified in 13 
unrelated Italian families with Lynch syndrome. Interestingly, 10 of the families carrying exon 8 deletions 
were of Sardinian origin, although the large majority of the probands with MSH2 mutations in our series of 
families did not have a Sardinian origin. Eight of the 10 Sardinian families shared the same deletion 
breakpoints, in cis to an identical haplotype, suggesting a founder effect. Testing for deletions is costly and 
time-consuming, and this can pose a relevant problem when testing for multiple at risk family members is 
required. For all five deletions, a quick PCR assay was developed to facilitate the screening of at risk family 
members. 
 
The implications of this result on the testing strategy of Lynch syndrome in Sardinia are discussed. 
 
Patients and methods 
 
Subjects and samples 
 
The 13 families with MSH2 exon 8 deletions presented here were identified from a subset of 66 unrelated 
families with clinical suspect of Lynch syndrome found to carry a mutation in the MSH2 gene. Samples were 
tested in Turin. 
Out of 66, 15 of the MSH2 mutation-positive families, 14 of which collected in Cagliari, share a Sardinian 
origin, while the majority (51/66) were collected in the Turin area and originate from other Italian regions, 
mainly northwestern. One family of Sardinian origin was collected in Turin. Ten out of 13 families carrying 
MSH2 exon 8 deletions were from Sardinia. Two Sardinian families counted many members: 26 affected 
individuals in four generations in family M, and 16 affected individuals in three generations in family C 
(Table 1). Some members from the largest family live in different towns in northern Italy. 
 
Table 1. Clinical features of Lynch syndrome families with exon 8 deletion of MSH2 gene 
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A AC-I 8 
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1 
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0 0 1/1 1/1 1 0 0/2 
B BR 2 
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1 0 1/1 1/1 1 0 1/2 
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4 1 3/3 3/3 1 4/4 11/21 
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43 
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L BR 4 
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  20 
42 
(30–
51) 
14 
8 
(2) 
1 
(1) 
0 0 1/1
a 1/1b 4 9/9 14/27 
N AC-I 4 
48 
(42–
50) 
4 
0 
(0) 
0 
(0) 
0 0 1/1 1/1 3 0 0/3 
P 
AC-
II 
6 
38.5 
(35–
49) 
5 
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(1) 
0 
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0 0 1/1 1/1 0 3/3 1/3 
Q AC-I 5 
40 
(33–
52) 
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0 
(0) 
1 
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 Abbreviations: AC-I, Amsterdam criteria type 1; AC-II, Amsterdam criteria type 2; LS, Lynch syndrome; CRC, 
colorectal cancer; EC-OC, endometrial and ovarian cancer; GC-SBC, gastric and small bowel cancer; IHC, 
immunohistochemistry; PC, pancreatic cancer; UUC, upper urinary cancer. 
 Clinical criteria: BR, AC-I, AC-II, number of individuals affected by LS, tumors: CRC, EC-OC, GC-SBC, PC, UUC. No 
hepatobiliary cancers were present. Given the uncertain diagnosis, central nervous system tumors and skin cancer 
were not taken into consideration. 
 *Median age calculated on three affected individuals. 
a Only one microsatellite (BAT26) was tested. 
b IHC for MSH6 was not performed. 
In family N, the mutation analysis was carried out on three healthy siblings, whose father, affected by 
metachronous colon cancers and suspected for Lynch syndrome, had died. In one sibling an MSH2 exon 8 
deletion was found (Table 2). 
 
 
Table 2. Molecular characterization of the deletions and clinical features of the probands 
Patient MSH2 ex 8 deletion 
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RNA 
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analyzed 
/cancer 
site (age) 
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MS-
stat
us 
IHC 
A 
c.1277−1180_1386+2226del3516insCAT
TCTCTTTGAAAA 
Nonrepeti
tive 
AluSp 
ND 
Transverse 
(<50) 
MSI-
H 
MSH2−/MS
H6− 
B 
c.1277−1180_1386+2226del3516insCAT
TCTCTTTGAAAA 
Nonrepeti
tive 
AluSp 
  
Rectum 
(<50) 
    
        
Ascending 
(<50) 
MSI-
H 
MSH2−/MS
H6− 
        
Small bowel 
(<50) 
    
C 
c.1277−1180_1386+2226del3516insCAT
TCTCTTTGAAAA 
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r.1277_1386d
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Ascending 
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 Abbreviation: ND, not done. 
a Only BAT26 was tested. 
 
 
Following the identification of the deletion in the index cases, 98 family members were tested. The clinical 
features of all probands are reported in Table 2. 
 
All families met the Amsterdam or the revised Bethesda criteria. 
 
Informed consent was obtained from all subjects included in this study, which fulfilled the policies of the 
local ethical committee. 
 
DNA extraction 
 
Genomic DNA was extracted from peripheral blood leukocytes, using the QIAamp DNA Blood Mini kit 
(Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. 
 
DNA from tumors and normal tissues was isolated from formalin-fixed paraffin-embedded specimens after 
overnight digestion with lysis buffer and proteinase K (Qiagen GmbH). Manual light-microscope 
microdissection allowed us to obtain over 80% tumor cells. 
 
Immunohistochemistry 
 
Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissues. 
 
Antigen retrieval was performed at high temperature by microwave heating. Slides were incubated with 
mouse monoclonal antibodies against MLH1 (BD Pharmingen, San Diego, CA, USA, clone G168–15), MSH2 
(BD Biosciences Transduction Laboratories, San Diego, CA, USA, clone 27) and MSH6 (BD Biosciences 
Transduction Laboratories, clone 44) proteins. Visualization was performed by application of HRP-linked 
secondary antibody (EnVision DakoCytomation, Glostrup, Denmark) and diaminobenzidine. 
 
Protein staining of MLH1, MSH2 and MSH6 was scored as positive (normal expression) in presence of 
nuclear staining of cancer and adjacent non-neoplastic cells; negative (abnormal staining) when tumor cells 
showed loss of nuclear staining with concurrent staining of non-neoplastic cells nuclei.9, 10 
 
Detection of Microsatellite Instability (MSI) 
 
MSI status was tested matching the length of three mononucleotide repeats (BAT25, BAT26 and BAT40) 
between tumor and normal DNA from all available cancers (16 tissues). 
 
Microsatellites were considered unstable if one or more novel alleles were present in the PCR product of 
the tumor sample compared with the PCR product of the normal tissue from the same individual. A tumor 
was considered to be MSI-H if at least 2/3 of the amplified markers were unstable.9, 11 
 
MLPA, DHPLC and real-time PCR 
 
Large deletions were screened using Multiplex ligation-dependent Probe Amplification SALSA MLPA KIT 
P003 MLH1/MSH2 according to manufacturer’s protocol (MRC-Holland, Amsterdam, The Netherlands). The 
amplified products were separated on an ABI 3100 Avant sequencer and analyzed by Genescan software 
(Applied Biosystems, Foster City, CA, USA).6 
 
In all individuals showing MSH2 exon 8 deletion the exon 8 was analyzed by DHLPC (Transgenomic, Inc., 
Omaha, NE, USA) or sequencing (ABI 3100 Avant Genetic Analyzer–Applied Biosystems) to exclude the 
presence of a variant that could have affected the binding of the MLPA exon 8-specific probes. 
 
All deletions were confirmed by real-time PCR analysis, carried out as a duplex-PCR reaction amplifying 
MSH2 exon 8 (target) and RnaseP (internal control). TaqMan fluorescent probe and forward/reverse 
primers for exon 8 were synthesized by Applied Biosystems and used at 250 and 900 nM, respectively. 
 
RNA extraction and transcript analysis 
 
The RNA of selected cases was extracted from blood collected in PAXgene tubes (PreAnalytics GmbH, 
Hombrechtikon, Switzerland) using the PAXgene Blood RNA kit (Qiagen GmbH). The cDNA was generated 
with Transcripter first strand cDNA synthesis kit (Roche Diagnostics GmbH, Mannheim, Germany). 
 
RT-PCR amplification was performed using forward and reverse primers located on exon 7 and exon 9, 
respectively. 
 
Molecular characterization of the deletions 
 
Sequences of intron 7 (15.6 kb) and intron 8 (17.4 kb) were analyzed by RepeatMasker and primers for 
long-range PCR (LR-PCR) were designed to avoid repeated sequences. LR-PCR performed on genomic DNA 
(300 ng) using several combinations of primer pairs, allowed to progressively narrow the regions containing 
the breakpoint junctions. 
 
The Expand Long Template PCR system kit (Roche Diagnostics GmbH) was used according to the 
manufacturer's protocol. The annealing temperature of the primer pairs ranged between 66and 62 °C and 
the extension time was 4 min+20 s/cycle. 
 
PCR products were electrophoresed on 1% agarose gel to assess the presence of abnormally sized bands. 
The abnormal bands were excised from the gel and DNA was extracted and purified using the QIAquick gel 
extraction kit (Qiagen GmbH). The product was sequenced on ABI Prism 3100 Avant. 
 
Primers for sequencing were designed either upstream/downstream from repetitive nucleotide stretches 
or based on information obtained from restriction enzymes digestion of the amplified products and from 
previously performed sequences. 
 
To analyze at risk individuals belonging to the families with the 19280, 11170 and 6005 nucleotides 
deletions, we developed three different duplex-PCR assays, each with two pairs of primers: one amplifying 
the specific fragment encompassing the deletion and the second amplifying TSC2 exon 28 as a control. In 
healthy individuals only the amplicon of TSC2 exon 28 was obtained. The primers used in LR-PCR, 
sequencing and duplex-PCR are listed in Supplementary Table 1. 
 
Mutation nomenclature and reference sequences 
 
Mutations were named following the HGVS recommendations.12 MSH2 gene mRNA and DNA RefSeq are 
NM_000251.1 and NG_007110.2. The location of the SNPs used for haplotype analyses is derived from 
chromosome 2, contig NT_022184.15 of Ref. GRCh37.p5 assembly. 
 
 
 
Haplotype analysis 
 
Nine polymorphic markers telomeric and centromeric to MSH2, spanning 0.3 Mb of chromosome 2, were 
tested in the families by segregation analysis, to construct the haplotypes carrying the deletions. The 
markers location on chromosome 2 is reported in Table 3 and the physical distance of each marker from 
MSH2 is shown in Figure 1a. 
 
Figure 1. 
 
Characteristics of the five MSH2 exon 8 deletions. (a) Map of the simple nucleotide polymorphisms surrounding MSH2 
used to define the haplotypes carrying the exon 8 deletions. (b) Zoom-in of introns 7 and 8 to show the breakpoints 
position – described at the upper end of the vertical dotted lines – and the size in bp of five different deletions (black 
bars). (c) Approximate location of the primers used for LR-PCR. 
 
 
 
 
 
Table 3. Haplotypes identified in 13 families harboring MSH2 exon 8 deletions 
 
 
 
 
 
 
 
 
Data analysis from HapMap (release 24, CEU population) and Haploview v. 4.113 led to the identification of 
five Tag SNPs (rs1126497, rs3924917, rs748780, rs6736039 and rs1863334) representative of different 
linkage blocks. In addition, three short repeat markers were chosen from the UCSC Genome Browser (Feb 
2009 (GRch37/hg19), upstream and downstream from the region covered by the previous Tag SNPs: 
rs66719305, rs72198494 and rs10525052. Another deletion/insertion polymorphism (−/GT) (rs67972878), 
12 bp upstream from rs3924917, was included. Allele frequencies of SNPs reported in the HapMap-CEU 
population are: rs1126497 (C=0.496/T=0.504); rs3924917 (A=0.403/G=0.597); rs748780 (C=0.425/T=0.575); 
rs6736039 (G=0.571/T=0.429); rs1863334 (T=0.588/G=0.412). 
 
Topof page 
Results 
 
Between 2001 and 2011, 126 heterozygous germline mutations (66 in MSH2, 48 in MLH1 and 12 in MSH6) 
were identified among the index cases undergoing genetic analysis in Turin for suspected Lynch syndrome. 
Among the deleterious mutations, 29 were genomic deletions (25 in MSH2, 3 in MLH1 and 1 in MSH6). In 
particular, MLPA analysis identified a heterozygous deletion of MSH2 exon 8 in 13 probands, 10 of which of 
Sardinian ancestry. Most families (10 out 13) fulfilled the Amsterdam criteria and included multiple cases of 
colorectal and extracolonic cancers typical of Lynch syndrome. Tumor tissue analysis showed high MSI and 
loss of expression of the MSH2 and MSH6 proteins in all 16 tumors available from the 13 families. Of the 98 
relatives analyzed, 19 were affected by Lynch syndrome-related cancers and found to carry the mutation; 
predictive testing showed the presence of the deletion in 38/79 healthy relatives (Table 1). 
 
DHPLC or sequence analysis of MSH2 exon 8 excluded the presence of heterozygous variants affecting the 
binding of the MLPA probe. All deletions were confirmed with real-time PCR. 
 
Several LR-PCRs were performed using different pair of primers to pinpoint the deletion breakpoints: direct 
sequencing of PCR products of unexpected size led to the identification of five different genomic deletions 
(Figures 1b and c). 
 
In patients belonging to eight families of Sardinian Ancestry (A, B, C, D, E, F, G and H, panel S.1), LR-PCR 
performed with primers located 2 kb upstream (M2i7DF) and 4 kb downstream (M2i8BR) of MSH2 exon 8 
showed a 6-kb expected band and a novel 2.7-kb band (Figure 3a). Sequencing identified a 3516-bp 
deletion with a 15-bp insertion. The breakpoints involve a nonrepetitive sequence in intron 7 and an 
inverted AluSp element in intron 8. The interposed sequence of 15 nucleotides is not present in the MSH2 
gene, and it is too short for BLAST analysis. This deletion can be described as c.1277–
1180_1386+2226del3516insCATTCTCTTTGAAAA (Figure 2a, Supplementary Figure 1). 
 
Figure 2. 
Breakpoint junctions in different exon 8 deletions of MSH2. Panel (a) two deletions of Sardinian origin S.1, 
c.1277−1180_1386+2226del3516insCATTCTCTTTGAAAA; S.2, c.1276+198_1386+3761del19280. Panel (b) three deletions 
found in three families of non-Sardinian origin. Family N, c.1277−6284_1386+4776del11170; family P, c.1277–
6224_1386+4836del11170; family Q, c.1277–4076_1386+1819del6005. 
 
 
 
 
 In probands from families L and M (panel S.2), both of Sardinian ancestry, the LR-PCR was fulfilled using a 
forward primer in exon 7 (M2e7F) and the M2i8BR reverse primer spanning a region of 19.9 kb. Gel 
electrophoresis showed a single abnormal band of <1 kb. The sequencing of that fragment led to the 
identification of a 19280-bp deletion. 
The breakpoint is located within two inverted AluSx in a 13-bp region of complete homology. On the basis 
of the most 3′ nucleotide change within the upstream AluSx the deletion can be described as 
c.1276+198_1386+3761del19280 (Figure 2a, Supplementary Figure 2). 
 
We subsequently set up a duplex-PCR and real-time PCR to confirm the MLPA result on the index patients 
or to test relatives at risk of inheriting this deletion, with the same primers used in LR-PCR and primers 
amplifying exon 28 of TSC2 (Figure 3b: lanes 1 and 2). 
 
 
Figure 3. 
 
Long-range PCR (LR-PCR) and duplex-PCR developed for rapid identification of MSH2 exon 8 deletions. (a) LR-PCR 
product from a subject with exon 8 deletion from the S.1 group, run in a 1% agarose gel electrophoresis. M, size 
markers from Lambda DNA/EcoR I/Hind III cut (Fermentas UAB, Vilnius, Lithuania). Lane 1, deletion of 3615 bp (2.7 kb 
band); lane 2, normal control (6.2 kb band). (b) Duplex-PCR product from a subject with exon 8 deletion from the S.2 
group (lane 1), and from two individuals with exon 8 deletion from family P (lane 3) and family Q (lane 5), 
respectively. M lane on the left, size markers from pUC19 DNA/MspI cut (Fermentas UAB); M lane on the right, size 
markers from GeneRuler 100 bp Plus DNA Ladder (Fermentas UAB). Lane 1, 19 280 bp deletion (663 bp band); lane 3, 
11 170 bp deletion (880 bp band); lane 5, 6005 bp deletion (727 bp band). All lanes from deletion carriers and normal 
controls (the latter in lanes 2, 4 and 6), show a 227-bp band co-amplified by a selected pair of primers, as a positive 
internal control. Indeed, the primers used in panel (b) cannot produce any product from normal samples because of 
the large size of the expected fragments. 
 
 
 
 
 In probands from families N and P (non-Sardinian families), LR-PCR yielded an abnormal band of ~4.5 kb 
with a third pair of primers (M2i7BF/M2i8CoR). The use of restriction enzymes allowed to narrow the 
region containing the breakpoints. In both samples, the recombination took place between two AluY 
elements on the same strand, but the breakpoints are slightly different. In family N the breakpoint is 
located in a 5-nucleotide identical segment, and the change at the most 3′ position allows to describe this 
deletion as c.1277–6284_1386+4776del11170. 
 
In family P the breakpoint is located in a 13-nucleotide identical segment, and the deletion can be 
described as: c.1277–6224_1386+4836del11170 (Figure 2b). 
 
A duplex-PCR using the same primers was developed to test the relatives both families N and P (Figure 3b: 
lanes 3 and 4). 
 
No pair of primers previously used was successful in amplifying the deleted allele in the index case of family 
Q. An abnormal band of ~3 kb in size was obtained using a novel forward primer located 4.8 kb upstream 
and the same reverse primer 4 kb downstream from exon 8 (M2iI7EF/M2i8BR). The region containing the 
breakpoints was narrowed using restriction enzymes. A novel reverse primer was designed for sequencing. 
The breakpoints are located within an AluSz6 and a 13-bp sequence interposed between an AluSp and an 
AluJr. The recombination led to a 6005-bp deletion: c.1277–4076_1386+1819del6005 (Figure 2b). 
 
A duplex-PCR was developed to identify carriers of the deletion (Figure 3b: lanes 5 and 6). 
 
Supplementary Figure 1 shows the alignments of the Alus around the deletion breakpoints of families L and 
M, N, P. 
 
cDNA analysis was performed on 5 of 13 index cases belonging to families C, G, M, P and Q (Table 2). In all 
available samples, this analysis showed both the normal and the short transcript lacking exon 8: 
r.1277_1386del110 (data not shown). 
 
The molecular characterization of the deletions and the results of tumor tissue analyses are are 
summarized in Table 2. 
 
To define a possible origin of the recurrent deletions from a common ancestor, haplotype analysis was 
performed using nine polymorphic markers located both upstream and downstream from the MSH2 gene. 
Haplotypes were reconstructed genotyping all available informative relatives from each family, except for 
family G, in which only the index case was genotyped as no biological samples from relatives were 
available. The same haplotype segregates with the deletion c.1277−1180_1386+2226del3516ins15 in all 
seven fully informative Sardinian families (A, B, C, D, E, F and H). It is worth noting that the genotype of the 
proband of family G, also of Sardinian origin, does not exclude a linkage of exon 8 deletion with the 
haplotype mentioned above. Haplotypes are shown in Table 3. 
 
Discussion 
 
In this study we analyzed all cases of MSH2 exon 8 deletions ascertained in our laboratory, in order to 
define the extension of the deletion and investigate possible founder effects. 
 
We identified proximal and distal breakpoints in all thirteen families with exon 8 deletions. 
 
These rearrangements appear to originate by recombination between a nonrepetitive element and an Alu 
sequence (S.1 group and family Q), or by homologous recombination between two Alus on the same strand 
(S.2 group, N and P families), in agreement with data previously reported by other authors.5, 14, 15, 23 Five 
different deletions were identified. One (c.1276+198_1386+3761del19280) had been previously reported in 
a single family5 and we were subsequently able to link our proband of family M to the same large family 
from Sardinia. 
 
Desai et al16 and Froggatt et al17 reported that the high density of Alu sequences in the MSH2 gene may 
give rise to identical genomic rearrangements in consequence of independent mutational events. In two 
Italian families (N and P), similar but not identical deletions have been identified: both deletions span 
11170 nucleotides and involve the same Alu, but the rearrangements arise in different points. Moreover, 
these deletions are associated with two different haplotypes, supporting the evidence of two independent 
mutational events. 
 
Seven Sardinian families, with the c.1277–1180_1386+2226del3516ins15 deletion, share an identical 
haplotype, spanning 0.3 Mb. Except for one family in which the haplotype was followed across three 
generations, the analysis was conducted on informative individuals from two generations, in order to 
define the phase. The haplotype of the eighth Sardinian family with the same deletion could not be 
obtained in absence of available relatives, although the proband’s genotype is compatible with the 
haplotype shared by the other families carrying the same deletion. 
 
It is noteworthy that the deletion c.1277−1180_1386+2226 del3516ins15 is per se a founder mutation, as 
the breakpoints include the same 15-nucleotides insertion. These eight families belong to different villages 
of southwestern Sardinia, each counting ~1200–7000 inhabitants (Figure 4), although a common ancestor 
was not recognized to the best of our knowledge. 
 
 
Figure 4. 
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Geographical origin of Sardinian families with MSH2 exon 8 deletions. Filled circles represent the eight families with the S.1 deletion 
(c.1277−1180_386+2226del3516insCATTCTCTTTGAAAA), the triangle represents the two families with the S.2 deletion (c.1276+198_1386+ 
3761del19280), which originate from the same town. 
 
 
 
 
 
Families M an L share the same 19280 bp deletion (c.1276+198_1386+3761del19280) and the same 
haplotype and, even if a consanguinity is not evident dating back four generations, both families originate 
from the same Sardinian village of 2000 inhabitants (Figure 4). 
 
Many founder mutations have been described in MSH2.5, 8, 17, 18, 19, 20, 21, 22, 23, 24 In a genetic 
isolate, such as Sardinia used to be (Sardinia currently counts about 1 673 000 inhabitants), a haplotype 
may be highly frequent because of genetic drift. Therefore, a mutation occurred on a particular haplotype 
can be traced in many individuals with a common ancestor. 
 
Within our families we didn't find recombination between the tested markers, but in some cases the 
centromeric markers were not informative. 
 
Except for the deletion previously described by Stella et al,5 the other exon 8 deletions found in our 
families are different from those previously characterized and reported4, 7, 25 in the LOVD (Leiden Open 
Variation Database) database. 
The identification of the breakpoint junctions allowed us to develop additional methods to screen for each 
deletion beside the use of MLPA and real-time. 
 
Each deletion described in this paper can now be detected by a quick test as LR-PCR or duplex-PCR (Figure 
3). This gives an advantage over more costly and time-consuming methods, as MLPA and/or real-time PCR, 
and is particularly useful when very large families are to be tested: for instance, in two of the Sardinian 
families described in this work (M and C), the predictive test was performed on a total of 48 healthy 
individuals. 
 
It is remarkable that mutations in MSH2 were identified in 75% of our Lynch syndrome Sardinian families 
(15/20). Most importantly, exon 8 deletions represent 66% (10/15) of Sardinian MSH2 mutations and 50% 
of all mutations in the three major MMR genes (data not shown), though our sample of Sardinian families is 
small. The only previously published work, to our knowledge, addressing MMR gene mutation frequencies 
in Sardinia, did not include testing for large deletions.24 The high frequency of MSH2 exon 8 deletions in 
Sardinian families with suspect Lynch syndrome is mainly due to the presence of the ancestral mutation 
identified in eight families, and provides a useful diagnostic indication. Indeed, our quick test for each of 
the two founder deletions represents a valuable first step analysis in probands whose tumors show high 
MSI associated with loss of MSH2 protein. 
 
This approach cannot be successfully applied to non-Sardinian Italian patients, as exon 8 deletions are quite 
rare in our series of mut-positive families (3/106, representing 3/51 of total MSH2 mutations) and the three 
identified deletions have different breakpoints. Therefore, the duplex-PCR can only be used to screen 
relatives belonging to those three families. 
 
Our work can have useful implications in the molecular diagnostics of Lynch syndrome: it allows a quick 
predictive test in healthy relatives of individuals with known exon 8 deletions and a first level analysis in 
patients of Sardinian origin. 
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